Immunogenicity of Biopharmaceuticals

Editors:

ISBN: 978-0-387-75840-4 (Print) 978-0-387-75841-1 (Online)

Table of contents (13 chapters)

  1. Front Matter

    Pages I-XI

  2. No Access

    Book Chapter

    Pages 1-25

    Immune Reactions Towards Biopharmaceuticals – a General, Mechanistic Overview

  3. No Access

    Book Chapter

    Pages 27-56

    Clinical Aspects of Immunogenicity to Biopharmaceuticals

  4. No Access

    Book Chapter

    Pages 57-73

    Assessment of Unwanted Immunogenicity

  5. No Access

    Book Chapter

    Pages 75-95

    Models for Prediction of Immunogenicity

  6. No Access

    Book Chapter

    Pages 97-111

    Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity, and Biosimilars

  7. No Access

    Book Chapter

    Pages 113-126

    Case Study: Immunogenicity of rhEPO

  8. No Access

    Book Chapter

    Pages 127-136

    Case Study: Immunogenicity of Interferon-Beta

  9. No Access

    Book Chapter

    Pages 137-146

    Case Study: Immunogenicity of Insulin

  10. No Access

    Book Chapter

    Pages 147-171

    Case Study: Immunogenicity of Factor VIII

  11. No Access

    Book Chapter

    Pages 173-187

    Case Study: Immunogenicity of Natalizumab

  12. No Access

    Book Chapter

    Pages 189-203

    Case Study: Immunogenicity of Anti-TNF Antibodies

  13. No Access

    Book Chapter

    Pages 205-238

    Heparin-Induced Thrombocytopenia

  14. No Access

    Book Chapter

    Pages 239-258

    Presenting an Immunogenicity Risk Assessment to Regulatory Agencies

  15. Back Matter

    Pages 259-263